Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNO 1016 in Acute Rhinosinusitis
NCT01146860Phase 3Completed
- Sponsor
- Bionorica
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute rhinosinusitis (ARS) comparing BNO 1016 with Placebo (2 arms). Primary endpoint: Major Symptom Score Assessed by the Investigator at 14 days. Started Jan 2010; status: completed.
02
Drugs
Sinupret extract
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NCT01146860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146860.